Tenvie Therapeutics
Precision small molecules transforming the treatment of neurological disease
Brisbane, United States · Founded 2025
- Headquarters
- Brisbane, California
- Employees
- 11–50
- Founded
- 2025
- Business Model
- B2B
About
Tenvie Therapeutics is a biotechnology company developing precision-engineered small molecule therapies to address core drivers of neurological and peripheral diseases, including neuroinflammation and cellular dysfunction. The company's platform uniquely enables both fully CNS-penetrant and peripherally restricted molecules, advancing a broad pipeline of programs across neurological, cardiometabolic, and ophthalmic indications. Its two most advanced programs — TNV262, a CNS-penetrant NLRP3 inhibitor, and TNV108, a peripherally restricted SARM1 allosteric inhibitor — are in Phase 1 clinical development. Tenvie launched in January 2025 with $200 million in funding led by ARCH Venture Partners, F-Prime Capital, and Mubadala Capital.
Summary
Tenvie Therapeutics is a Biotech company based in Brisbane, United States, founded in 2025.
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...